The price of Verona Pharma Plc ADR (NASDAQ:VRNA) shares last traded on Wall Street rose 0.08% to $104.85.
VRNA stock price is now 27.13% away from the 50-day moving average and 83.23% away from the 200-day moving average. The market capitalization of the company currently stands at $8.93B.
With the price target of $170, Wolfe Research recently initiated with Outperform rating for Verona Pharma Plc ADR (NASDAQ: VRNA). On April 28, 2025, TD Cowen recently initiated its ‘Buy’ rating on the stock quoting a target price of $100, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Fisher Andrew, General Counsel sold 80,000 shares of the company’s stock on Jun 16 ’25. The stock was sold for $922,000 at an average price of $11.53. Upon completion of the transaction, the General Counsel now directly owns 359,999 shares in the company, valued at $37.75 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 11 ’25, Chief Financial Officer Hahn Mark W sold 400,000 shares of the business’s stock. A total of $4,560,360 was realized by selling the stock at an average price of $11.40. This leaves the insider owning 12,278,992 shares of the company worth $1.29 billion. A total of 9.87% of the company’s stock is owned by insiders.
During the past 12 months, Verona Pharma Plc ADR has had a low of $16.91 and a high of $104.93. As of last week, the company has a debt-to-equity ratio of 1.08, a current ratio of 8.86, and a quick ratio of 8.73. The fifty day moving average price for VRNA is $82.4726 and a two-hundred day moving average price translates $57.2241 for the stock.
The latest earnings results from Verona Pharma Plc ADR (NASDAQ: VRNA) was released for 2025-03-31. The net profit margin was -138.52% and return on equity was -72.73% for VRNA.
